The role of l-arginine and ADMA in early neurological deterioration and early recurrence in patients with acute cerebral infarction

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029401

Enrollment

Unknown

Registered

2020-01-29

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral infarction

Interventions

Experimental group:L-arg

Control group:conventional treatment

Eligibility

Sex/Gender

All

Age

35 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. First onset cerebral infarction patient; 2. Aged 35 ~ 80 years old; 3. the course of the disease is within 48; 4. the patient has corresponding symptoms and signs of focal nervous system defect; 5. head CT, MRI or DWI imaging confirmed acute cerebral infarction; 6. informed consent and good compliance.

Exclusion criteria

Exclusion criteria: 1. exclude patients with severe infection and autoimmune diseases; 2. patients with malignant tumor, atrial fibrillation, thyroid disease and severe liver and kidney dysfunction should be excluded; 3. exclude cerebral hemorrhage, brain tumor, hemorrhagic cerebral infarction, Parkinson's disease, epilepsy and other neurological diseases; 4. exclude patients with a history of myocardial infarction within 3 months; 5. exclude patients who have taken drugs within 3 months (such as methotrexate, antiepileptic drugs, etc.) that affect the results of this study; 6. exclude thrombolytic patients; 7. coma patients.

Design outcomes

Primary

Measure	Time frame
END;Early recurrence;	—

Countries

China

Contacts

Public ContactYuanwei Wang

Shuyang People's Hospital

wyweilmn@126.com+86 13041019313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026